eGPA and Local Inflammation Within the Ear, Nose and Throat Area

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Medical Center Groningen

About this trial

Rationale: Eosinophilic Granulomatosis with Polyangiitis (eGPA), eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) are airway diseases where eosinophils and interleukine-5 are involved in the pathogenesis. eGPA differs from the other diseases with respect to involvement of other organs. The investigators hypothesize that nasal microbiome dysbiosis with a central augmenting role for S. Aureus plays an important role in disease expression. The investigators expect that anti-interleukin-5 treatment with mepolizumab restores the changes of the nasal microbiome and immune responses to a healthy control phenotype. To study this, the nasal microbiome, the local and systemic immune response and the effect of mepolizumab treatment will be assessed.

Eligibility criteria

Qualifiers

18 years of age

able to give informed consent

In CRSwNP group: availability of bilateral nasal polyps as diagnosed by endoscopy or CT scan

In Severe asthma group: clinical diagnosis of asthma with forced expiratory volume at one second(FEV1) <80% AND either FEV1 reversibility >12% initial or documented positive metacholine challenge (PC20 < 8 mg/ml)

Disqualifiers

unable to give informed consent

Active smoking < (less than) 6 months from baseline visit

Concomitant use of dupilumab within 6 months of baseline visit

pregnant or breastfeeding woman

Trial design

Treatments tested in this trial

  • laboratory experiments before and after mepolizumab treatment

Treatment groups

150 Participants
are divided into 5 treatment groups

Sponsors and collaborators